Wagner Paul A.

SEE REMARKS, DirectorForte Biosciences, Inc. (FBRX) · full profile →Form 4 · filed Aug 27, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
11
1 non-derivative · 10 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 27, 2026Tender(U)85K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 27, 2026Disposed to issuer(D)17K0
Aug 27, 2026Disposed to issuer(D)5K0
Aug 27, 2026Disposed to issuer(D)12K0
Aug 27, 2026Disposed to issuer(D)44K0
Aug 27, 2026Disposed to issuer(D)920K0
Aug 27, 2026Disposed to issuer(D)270K0
Aug 27, 2026Disposed to issuer(D)500K0
Aug 27, 2026Disposed to issuer(D)3K0
Aug 27, 2026Disposed to issuer(D)180K0
Aug 27, 2026Disposed to issuer(D)4K0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001612842-26-000011) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Ask your agent about FBRX insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001612842-26-000011"
Ask your agent
Use Arkolith to summarize insider buying and selling at Forte Biosciences, Inc.
over the last 90 days and cite the filings.